December 15, 2009 /
MS Research Study and Reports
I first wrote a blog post of this story yesterday.
Below is another posting (even better than yesterday’s post):
Multiple Sclerosis Treatment with Adult Stem Cells
by David Prentice
December 14, 2009
The latest success story comes from Australia. Ben Leahy, 20, was in a wheelchair and experiencing vision problems when he was treated earlier in 2009. Ben is now walking after treatment with adult stem cells. The treatment involves isolating the patient’s bone marrow adult stem cells, giving the patient mild chemotherapy to destroy the rogue immune cells that are attacking the nervous system, then re-injecting the patient’s adult stem cells.
While the Australian group has not yet published their results, the technique mirrors the treatment results published in 2009 in Lancet Neurology by Dr. Richard Burt’s team at Northwestern, where they reported that they had reversed the neurological dysfunction of early-stage multiple sclerosis patients.
As Dr. Burt noted:
“This is the first time we have turned the tide on this disease.”
CLICK HERE to continue reading and to watch MS Patient videos of this treatment
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Keep up-to-date with MS related News (as seen above), when registered with us. Visit our website to register NOW. It will not take more than 30 seconds to register and once accomplished, you will then receive our weekly MS related e-Newsletter, which is currently being received in 58 countries by more than 6000 e-recipients. Click HERE to register. – Thank You
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
Categories
Latest Blog Posts
- New research findings challenge old beliefs about myelin repair in MS
- FDA OKs first human trial of oral MS remyelination therapy PTD802
- Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
- FDA clears CTA313 (Car-T Cellular Therapy) trial for progressive MS, autoimmune disease
- Multiple Sclerosis or Lupus: Can You Have Both?
- What to Know About the Link Between Multiple Sclerosis and Psoriatic Arthritis
- Is an MS Flare-Up the Same as a Relapse?
- Going Gluten-Free for MS? Here Are 5 Easy Recipes
- Blood Proteins Identified That Predict Multiple Sclerosis Early
- How to Have a Healthy Sex Life When You Have Multiple Sclerosis
- New anatomy of the clitoris and its implications for women with MS and their partners
- I Feel Like I Have MS Today ( a patient’s story)
- Is there a link between MS and Alzheimer’s (AD)
- What is Cog Fog (Cognitive or Brain Fog) and How to Deal with This Frequent MS Symptom
- Understanding the Genetics of Multiple Sclerosis
- CMSC 2026: Trial data show frexalimab benefits lasting 3 years
- Sedentary behavior and its correlates in adults with multiple sclerosis
- Key multiple sclerosis models reveal different damage timelines, offering roadmap for myelin repair studies
- Avoid These 7 Foods That Accelerate Aging
- AI Regulation & Transparency in Radiology with Dr. Hugh Harvey (ECR25)
